(Q30608935)

English

Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 June 2017

1 reference

based on heuristic

inferred from title

Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group (English)

1 reference

Europe PubMed Central

25 June 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Sharma D

1

1 reference

Europe PubMed Central

25 June 2017

Buyse M

2

1 reference

Europe PubMed Central

25 June 2017

Pitt B

3

1 reference

Europe PubMed Central

25 June 2017

Rucinska EJ

4

1 reference

Europe PubMed Central

25 June 2017

language of work or name

0 references

publication date

1 January 2000

1 reference

Europe PubMed Central

25 June 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

25 June 2017

85

1 reference

Europe PubMed Central

25 June 2017

2

1 reference

Europe PubMed Central

25 June 2017

187-192

1 reference

Europe PubMed Central

25 June 2017

Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Losartan in heart failure: preclinical experiences and initial clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Bias in the one-step method for pooling study results.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900646-3

7 January 2021

Identifiers

10.1016/S0002-9149(99)00646-3

1 reference

Europe PubMed Central

25 June 2017

1 reference

Europe PubMed Central

25 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30608935&oldid=1609776042"